Abstract

Antimicrobial stewardship programs (ASPs) focus on improving the utilization of broad spectrum antibiotics to decrease the incidence of multidrug-resistant Gram positive and Gram negative pathogens. Hospital admission for both medical and surgical intra-abdominal infections (IAIs) commonly results in the empiric use of broad spectrum antibiotics such as fluoroquinolones, beta-lactam beta-lactamase inhibitors, and carbapenems that can select for resistant organisms. This review will discuss the management of uncomplicated and complicated IAIs as well as highlight stewardship initiatives focusing on the proper use of broad spectrum antibiotics.

Highlights

  • Intra-abdominal infections (IAIs) are the second most common cause of infection-related mortality in intensive care units [1]

  • Authors commented that this finding may be due to the fact that appendicitis-associated pathogens generally arise from normal bowel flora and do not reflect the higher extended-spectrum beta-lactamase (ESBL) rates found in health care-associated

  • Patients randomized to antibiotic therapy had significantly higher rates of 30 day post-intervention peritonitis compared with the appendectomy group (8% vs. 2%, treatment difference 5.8; 95% CI, 0.3–12.1)

Read more

Summary

Introduction

Intra-abdominal infections (IAIs) are the second most common cause of infection-related mortality in intensive care units [1]. Common IAIs include appendicitis, diverticulitis and cholecystitis [1,2]. Recommendations for the diagnosis and management of complicated IAIs are reviewed in the Surgical Infection Society and the Infectious Diseases Society of America (SIS-IDSA). Tokyo Guidelines (TG13) for acute cholangitis and acute cholecystitis in 2013 [2,3,4]. These guidelines recommend antimicrobial therapy based on the severity and etiology of infection as well as the presence of underlying medical conditions. The treatment of IAIs involves a balance between optimizing antimicrobial therapy and reducing collateral damage of antimicrobial use, including emerging resistance and Clostridium difficile infections (CDI) [5,6].

Microbiology
Treatment
Conclusion
Diverticulitis
Cholecystitis
Antimicrobial Stewardship Initiatives
Findings
Conclusions

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.